OncoCyte Corporation (OCX): Price and Financial Metrics


OncoCyte Corporation (OCX)

Today's Latest Price: $5.85 USD

1.09 (22.90%)

Updated Jan 25 6:40pm

Add OCX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

OCX Stock Summary

  • OCX's price/sales ratio is 448.34; that's higher than the P/S ratio of 98.48% of US stocks.
  • With a year-over-year growth in debt of 591.49%, OncoCyte Corp's debt growth rate surpasses 96.93% of about US stocks.
  • As for revenue growth, note that OCX's revenue has grown 4,362.5% over the past 12 months; that beats the revenue growth of 99.73% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to OncoCyte Corp are MOTS, FUV, ITCI, IPWR, and TRVN.
  • Visit OCX's SEC page to see the company's official filings. To visit the company's web site, go to www.oncocyte.com.

OCX Stock Price Chart Interactive Chart >

Price chart for OCX

OCX Price/Volume Stats

Current price $5.85 52-week high $6.13
Prev. close $4.76 52-week low $1.15
Day low $5.26 Volume 4,357,100
Day high $6.13 Avg. volume 1,765,060
50-day MA $2.52 Dividend yield N/A
200-day MA $2.06 Market Cap 393.42M

OncoCyte Corporation (OCX) Company Bio


OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.


OCX Latest News Stream


Event/Time News Detail
Loading, please wait...

OCX Latest Social Stream


Loading social stream, please wait...

View Full OCX Social Stream

Latest OCX News From Around the Web

Below are the latest news stories about OncoCyte Corp that investors may wish to consider to help them evaluate OCX as an investment opportunity.

Why OncoCyte Shares Are Trading Higher Today

OncoCyte Corp (NYSE: OCX ) shares are advancing to their highest level since the middle of 2019 on above-average volume. Oncocyte said it has entered into definitive agreements with its two largest institutional investors, namely Pura Vida Investments and Broadwood Partners, to purchase about $25 million of its … Full story available on Benzinga.com

Benzinga | January 21, 2021

Oncocyte Announces $25 Million Registered Offering

Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum IRVINE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has entered into definitive agreements with its two largest institutional investors to purchase approximately $25 million of Oncocyte’s common shares in a registered offering priced at $3.424 per share (“at market”), which was the average of the last five closing prices. The lead investor in the of...

Yahoo | January 20, 2021

Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 23rd Annual Needham Virtual Growth Conference. Presentation details: Date: January 15, 2021 Time: 10:45am ESTInvestors can register for the conference here: https://wsw.com/webcast/needham103/ocx/Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, www.oncocyte.com.About Oncocyte Corporation Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across t...

Yahoo | January 12, 2021

Do Options Traders Know Something About OncoCyte (OCX) Stock We Don't?

Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.

Yahoo | December 17, 2020

ROCE Insights For OncoCyte Corporation Common Stock

In Q3, OncoCyte Corporation Common Stock (AMEX: OCX) posted sales of $555.00 thousand. Earnings were up 5.2%, but OncoCyte Corporation Common Stock still …

Benzinga | December 15, 2020

Read More 'OCX' Stories Here

OCX Price Returns

1-mo N/A
3-mo 272.61%
6-mo 300.68%
1-year 117.47%
3-year 44.44%
5-year 116.67%
YTD 144.77%
2020 6.22%
2019 63.04%
2018 -70.32%
2017 -34.04%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9065 seconds.